

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Vaniprevir Formulation

#### Manufacturer or supplier's details

Company : MSD  
Address : 199 Wenhai North Road  
HEDA, Hangzhou - Zhejiang Province - CHINA 310018  
Telephone : 908-740-4000  
Emergency telephone number : 86-571-87268110  
E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

**Appearance** : powder  
**Colour** : tan  
**Odour** : odourless

May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life.

#### GHS Classification

Specific target organ toxicity - repeated exposure : Category 2  
Short-term (acute) aquatic hazard : Category 3

#### GHS label elements

Hazard pictograms :

Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged or repeated exposure.  
H402 Harmful to aquatic life.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
**Response:**  
P314 Get medical advice/ attention if you feel unwell.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

### Physical and chemical hazards

Not classified based on available information.

### Health hazards

May cause damage to organs through prolonged or repeated exposure.

### Environmental hazards

Harmful to aquatic life.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Glycerides, C8-10	85409-09-2	>= 50 -< 70
Vaniprevir	923590-37-8	>= 10 -< 20

## 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2022/10/01
6.0	2023/04/04	25782-00021	Date of first issue: 2014/10/27

Protection of first-aiders : May cause damage to organs through prolonged or repeated exposure.  
: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

mine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

#### Handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents

#### Storage

- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Vaniprevir	923590-37-8	TWA	300 µg/m <sup>3</sup>	Internal

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear the following personal protective equipment:  
Safety goggles

Skin and body protection : Skin should be washed after contact.

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.

---

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : tan

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : 1 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, dynamic : No data available  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation  
Skin contact

---

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

Ingestion  
Eye contact

### Acute toxicity

Not classified based on available information.

### Components:

#### Glycerides, C8-10:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401  
Remarks: Based on data from similar materials

Acute inhalation toxicity : LD50 (Rat): > 1.86 mg/l  
Exposure time: 6 h  
Test atmosphere: dust/mist  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

#### Vaniprevir:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg  
Remarks: No adverse effect has been observed in acute toxicity tests.

LD0 (Dog): > 300 mg/kg  
Remarks: No adverse effect has been observed in acute toxicity tests.

LD50 (Mouse): > 2,000 mg/kg  
Remarks: No mortality observed at this dose.

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Glycerides, C8-10:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### Vaniprevir:

Species : Rabbit  
Result : No skin irritation

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Glycerides, C8-10:

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

##### Vaniprevir:

Species : Bovine cornea  
Result : Mild eye irritation  
Method : Bovine cornea (BCOP)

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Glycerides, C8-10:

Test Type : Buehler Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

##### Vaniprevir:

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Glycerides, C8-10:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative  
Remarks: Based on data from similar materials  
  
Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: Based on data from similar materials

### Vaniprevir:

Genotoxicity in vitro

: Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo

: Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Vaniprevir:

Species : Rat, male and female  
Application Route : Oral  
Activity duration : 104 Weeks  
:  $\geq 120$  mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Oral  
Activity duration : 6 Months  
:  $\geq 300$  mg/kg body weight  
: 75 mg/kg body weight  
Result : negative  
Target Organs : gallbladder

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Glycerides, C8-10:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

### Vaniprevir:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL:  $\geq$  250 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Development  
Species: Rat, female  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 120 mg/kg body weight  
Developmental Toxicity: LOAEC F1: 180 mg/kg body weight  
Symptoms: No specific developmental abnormalities  
Result: negative

Test Type: Development  
Species: Rabbit, female  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 120 mg/kg body weight  
Developmental Toxicity: NOAEL F1:  $\geq$  240 mg/kg body weight  
Symptoms: No specific developmental abnormalities  
Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Vaniprevir:

Exposure routes : Ingestion  
Target Organs : gallbladder, Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

### Repeated dose toxicity

#### Components:

##### Glycerides, C8-10:

Species	: Rat
NOAEL	: >= 1,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days
Method	: OECD Test Guideline 407
Remarks	: Based on data from similar materials

##### Vaniprevir:

Species	: Rat
NOAEL	: 120 mg/kg
LOAEL	: 360 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 15 mg/kg
LOAEL	: 30 mg/kg
Application Route	: Oral
Exposure time	: 9 Months
Target Organs	: Liver, gallbladder
Symptoms	: Gastrointestinal disturbance

Species	: Mouse
NOAEL	: 150 mg/kg
LOAEL	: 300 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Target Organs	: Liver, Kidney, Gastrointestinal tract, Heart, gallbladder, Stomach

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Vaniprevir:

Ingestion	: Symptoms: stomach discomfort, Diarrhoea, Nausea, Headache
-----------	---

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

### 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **Glycerides, C8-10:**

- |   |   |   |
|---|---|---|
| Toxicity to fish                                    | : | LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l<br>Exposure time: 96 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 203<br>Remarks: Based on data from similar materials              |
| Toxicity to daphnia and other aquatic invertebrates | : | EL50 (Daphnia magna (Water flea)): > 100 mg/l<br>Exposure time: 48 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 202<br>Remarks: Based on data from similar materials                 |
| Toxicity to algae/aquatic plants                    | : | NOEC (Desmodesmus subspicatus (green algae)): > 1 mg/l<br>Exposure time: 72 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials        |
|   |   | EL50 (Desmodesmus subspicatus (green algae)): > 10 - 100 mg/l<br>Exposure time: 72 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials |

##### **Vaniprevir:**

- |   |   |   |
|---|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 4 mg/l<br>Exposure time: 48 h<br>Method: OECD Test Guideline 202<br>Remarks: No toxicity at the limit of solubility                    |
|   |   | LC50 (Americamysis): > 4 mg/l<br>Exposure time: 96 h<br>Method: US-EPA OPPTS 850.1035<br>Remarks: No toxicity at the limit of solubility                                    |
| Toxicity to algae/aquatic plants                    | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility |
|   |   | NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility   |

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Persistence and degradability

#### Components:

##### Glycerides, C8-10:

Biodegradability : Result: Readily biodegradable.  
Remarks: Based on data from similar materials

##### Vaniprevir:

Biodegradability : Result: not rapidly degradable  
Method: OECD Test Guideline 314

### Bioaccumulative potential

#### Components:

##### Glycerides, C8-10:

Partition coefficient: n-octanol/water : log Pow: < 4

##### Vaniprevir:

Partition coefficient: n-octanol/water : log Pow: 4.12

#### Mobility in soil

No data available

#### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version 6.0      Revision Date: 2023/04/04      SDS Number: 25782-00021      Date of last issue: 2022/10/01  
Date of first issue: 2014/10/27

---

### 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable

##### IATA-DGR

UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

##### IMDG-Code

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

##### GB 6944/12268

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable

#### Special precautions for user

Not applicable

---

### 15. REGULATORY INFORMATION

#### National regulatory information

Law on the Prevention and Control of Occupational Diseases

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2022/10/01
6.0	2023/04/04	25782-00021	Date of first issue: 2014/10/27

### Yangtze River Protection Law

|| This product does not contain any dangerous chemicals prohibited for inland river transport.

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## 16. OTHER INFORMATION

Revision Date : 2023/04/04

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Trans-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2022/10/01
6.0	2023/04/04	25782-00021	Date of first issue: 2014/10/27

---

portation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN